News|Slideshows|February 7, 2023

Endotypes of Severe Asthma: 5 Questions on Pathways, Biomarkers, Biologics

Author(s)Leo Robert

Check your knowledge of mechanistic features of severe asthma, specific biomarker level cut offs, and impact of comorbid disease on choice of biologic treatment.

Key factors in choosing appropriate biologic therapy for a patient with severe asthma include consideration of the specific mechanistic pathway that underlies the presentation, investigation of biomarker levels, and evaluation of comorbid inflammatory disease.

Following are 5 questions on these topics that are based on a comprehensive review and international expert opinion published in the Journal of Allergy and Clinical Immunology: In Practice by a group of clinicians recognized internationally for knowledge of severe asthma and of biologic medications. Test your endotype IQ.


Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.


Latest CME